Capricorn Fund Managers Ltd Purchases New Shares in Jazz Pharmaceuticals PLC $JAZZ
Capricorn Fund Managers Ltd recently acquired a new stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the fourth quarter, purchasing 10,000 shares valued at approximately $1.7 million, signaling growing institutional interest. Major institutional investors collectively own 89.14% of the stock, with several funds significantly increasing their positions. Despite recent insider selling totaling about $14.18 million, analysts maintain a "Moderate Buy" consensus with an average price target of $215.38, following Jazz Pharmaceuticals' strong Q4 earnings beat.
JAZZ Financials: Revenue Breakdown, Margins & Competitor Comparison
This article analyzes Jazz Pharmaceuticals PLC's (JAZZ) financial performance, focusing on its revenue breakdown, profitability margins, and comparison with competitors like EXEL and MDGL. Xywav is identified as the largest revenue contributor, and while the company shows strong gross and operating margins, its Return on Equity is negative. The analysis provides crucial insights for investors evaluating JAZZ within the Pharmaceuticals industry.
Perpetual Ltd Lowers Stake in Jazz Pharmaceuticals PLC $JAZZ
Perpetual Ltd significantly reduced its stake in Jazz Pharmaceuticals PLC ($JAZZ) by 74.3% in the fourth quarter, selling 447,997 shares, now holding 154,650 shares valued at $26.29 million. This reduction comes amid recent insider selling totaling $14.18 million by insiders, who now collectively own 4.30% of the company. Despite the institutional sell-off, analysts largely maintain a "Moderate Buy" rating with an average target price of $215.38, following the company's recent earnings beat.
Insider Selling: Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Sells 6,000 Shares of Stock
Jazz Pharmaceuticals Director Bruce Cozadd sold 6,000 shares of JAZZ stock for $1.143 million on April 1, 2026, reducing his position by 1.54%. The sale was executed under a pre-arranged Rule 10b5-1 trading plan. The company recently exceeded quarterly EPS estimates with strong revenue growth, and analysts maintain a "Moderate Buy" rating with a target price of $215.38.
Director at Jazz Pharmaceuticals (JAZZ) sells 6,000 company shares
Bruce C. Cozadd, a director at Jazz Pharmaceuticals plc (JAZZ), sold 6,000 ordinary shares of the company on April 1, 2026, through open-market transactions. The sales were executed at weighted average prices between $190.2220 and $191.7447 per share and were made according to a pre-arranged Rule 10b5-1 trading plan adopted in November 2025. Following these transactions, Cozadd retained direct ownership of 384,682 ordinary shares in Jazz Pharmaceuticals.
Jazz Pharmaceuticals PLC (J7Z.HM) stock price, news, quote and history
The Yahoo Finance page provides detailed stock information for Jazz Pharmaceuticals PLC (J7Z.HM), including its current price, news, charts, and historical data. As of April 2, the stock was trading at 160.30 EUR, down 2.46%. The page also includes performance overview data comparing J7Z.HM's returns against the S&P 500, showing significant year-to-date and 1-year gains for Jazz Pharmaceuticals.
Jazz Pharmaceuticals to Participate in Needham Virtual Healthcare Conference
Jazz Pharmaceuticals plc announced its participation in the 25th Annual Needham Healthcare Conference. Company management will engage in a fireside chat on April 15, 2026, which will be accessible via an audio webcast on their investor relations website. A replay of the webcast will also be available for 30 days.
Jazz Pharmaceuticals (NASDAQ: JAZZ) Form 144 shows 6,000-share sale notice
Jazz Pharmaceuticals (NASDAQ: JAZZ) has filed a Form 144 indicating a proposed sale of 6,000 shares of common stock, with the transaction date noted as April 1, 2026, on Nasdaq. The filing also reveals a previous sale of 6,000 shares on March 3, 2026, which generated proceeds of $1,118,613.32. Bruce Cozadd is identified as the reporting person for this sale.
Retirement Systems of Alabama Cuts Stock Position in Jazz Pharmaceuticals PLC $JAZZ
Retirement Systems of Alabama reduced its stake in Jazz Pharmaceuticals PLC ($JAZZ) by 11% in the fourth quarter, selling 20,703 shares and retaining 167,698 shares valued at approximately $28.5 million. Insiders have also been net sellers, offloading 68,015 shares worth around $13.0 million over the past three months. Despite institutional selling, analysts generally maintain a "Moderate Buy" consensus rating with an average price target of $215.38, following Jazz Pharmaceuticals' recent beat on quarterly EPS and revenue estimates.
Jazz Pharmaceuticals Stock: Steady Growth in Neuroscience and Rare Diseases Drives Long-Term Value for Investors
Jazz Pharmaceuticals (ISIN: IE00B4Q5ZN47) is demonstrating steady revenue growth through its focus on neuroscience and rare disease therapies, appealing to investors seeking exposure to high-margin specialty pharmaceuticals. The company's business model leverages blockbuster products like Xyrem and Epidiolex, driven by orphan drug status and addressing unmet medical needs. North American investors should monitor upcoming earnings and pipeline advancements, including oncology and rare disease initiatives, as potential catalysts while being mindful of risks like patent cliffs and pricing pressures.
Jazz Pharmaceuticals plc (JAZZ) Stock Price | Live Quotes & Charts | NASDAQ
This page provides live stock quotes and charts for Jazz Pharmaceuticals plc (JAZZ), showing its current price, daily change, and percentage change. It also includes sections for analyst ratings, though no current ratings are available, and information regarding earnings, which is currently absent. The page prompts users to discover more insights and sign up for trade alerts.
Jazz projects $4.25B–$4.50B 2026 revenue while advancing rare disease and oncology launches
Jazz Pharmaceuticals projects revenue between $4.25 billion and $4.50 billion by 2026, driven by growth in its neuroscience and oncology portfolios. The company is particularly focused on advancing new product launches in rare diseases and oncology, which are expected to be key contributors to its future financial performance.
Hennion & Walsh Asset Management Inc. Increases Stake in Jazz Pharmaceuticals PLC $JAZZ
Hennion & Walsh Asset Management Inc. significantly increased its stake in Jazz Pharmaceuticals (NASDAQ:JAZZ) by 25.5% in the fourth quarter, now holding 47,535 shares valued at approximately $8.08 million. This comes despite recent insider selling, with corporate insiders divesting over $13 million worth of shares in the last 90 days. Wall Street analysts maintain a "Moderate Buy" consensus for JAZZ, with an average target price of $215.38.
Is Jazz Pharmaceuticals (JAZZ) Still Attractive After A 47% One Year Share Price Rally
Jazz Pharmaceuticals (JAZZ) has seen a 47.2% share price rally over the past year, currently trading around US$182.69. Despite this, a Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 76.5%, with an estimated intrinsic value of $776.61 per share. The company also appears undervalued based on its Price/Sales ratio of 2.64x compared to its industry average and Simply Wall St's proprietary "Fair Ratio" of 7.75x.
Is Jazz Pharmaceuticals (JAZZ) Still Attractive After A 47% One Year Share Price Rally
Jazz Pharmaceuticals (JAZZ) has seen a significant 47% share price rally over the last year but is still considered undervalued according to Simply Wall St's analysis. Both a Discounted Cash Flow (DCF) model and a Price-to-Sales (P/S) ratio analysis suggest the stock is trading at a substantial discount to its intrinsic value. The company currently holds a valuation score of 6/6, indicating it is undervalued across all checks.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Sixteen analysts have given Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) a "Moderate Buy" consensus rating with an average 12-month price target of $215.38. The company recently exceeded Q4 earnings expectations, reporting EPS of $6.64 against an estimated $6.49, with revenue increasing 8.1% to $1.20 billion. Despite recent insider stock sales totaling approximately $13.0 million, institutional investors hold a significant 89.14% stake in the company.
Vanguard amends Schedule 13G/A after realignment (JAZZ)
The Vanguard Group has filed an amended Schedule 13G/A for Jazz Pharmaceuticals plc (JAZZ), reporting 0 shares beneficially owned and 0% of the common stock. This change is due to an internal realignment on January 12, 2026, which led certain Vanguard subsidiaries to report their holdings separately, in reliance on SEC Release No. 34-39538. The amendment clarifies that The Vanguard Group no longer has beneficial ownership over securities held by these disaggregated subsidiaries.
SG Americas Securities LLC Has $23.12 Million Stake in Jazz Pharmaceuticals PLC $JAZZ
SG Americas Securities LLC significantly increased its stake in Jazz Pharmaceuticals PLC by 2,969.1% in Q4, now holding 136,024 shares valued at $23.12 million. Jazz Pharmaceuticals exceeded quarterly earnings and revenue expectations, reporting EPS of $6.64 and revenue of $1.20 billion, an 8.1% year-over-year increase. Analysts maintain a "Moderate Buy" rating for the stock with an average price target of $215.38.
A Look At Jazz Pharmaceuticals (JAZZ) Valuation After Its New Nutrition Alliance For Sleep Disorders
Jazz Pharmaceuticals recently announced a new nutrition alliance focused on sleep disorders, coinciding with strong share price performance. The stock is currently trading at US$189.15, with Simply Wall St's analysis suggesting it is 17.4% undervalued, at a fair value of $228.96, indicating a "Value-Growth" hybrid driven by its diverse cash flows from sleep, epilepsy, and oncology segments. However, this valuation depends on regulatory timelines and execution, with potential risks from generic competition.
JAZZ SEC Filings - Jazz Pharmaceuticals Plc 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to Jazz Pharmaceuticals Plc (JAZZ) SEC filings, including annual reports, quarterly earnings, material event reports, and insider trading forms. It features AI-assisted summaries to help interpret complex documents, covering clinical trial milestones, financial results, executive changes, and governance matters. The platform aims to help investors track Jazz Pharmaceuticals' regulatory disclosures, clinical progress, corporate actions, and financial reporting.
Jazz Pharmaceuticals (Nasdaq:JAZZ) - Stock Analysis
Jazz Pharmaceuticals (JAZZ) is trading at a significant discount to its fair value, with analysts forecasting a 22.3% stock price increase and earnings growth of 33.81% per year. The company's future growth is driven by new product launches and strategic acquisitions in neuroscience, rare cancers, and cannabinoid therapies, despite facing risks from patent expirations and high debt levels. Recent news highlights include strong financial performance, ongoing R&D, key product approvals, and insider selling activities.
MassMutual Private Wealth & Trust FSB Sells 7,073 Shares of Jazz Pharmaceuticals PLC $JAZZ
MassMutual Private Wealth & Trust FSB significantly reduced its stake in Jazz Pharmaceuticals PLC, selling 7,073 shares, which represents a 95.2% decrease in its holdings. Despite this, analysts are largely positive on JAZZ with a consensus "Moderate Buy" rating and a price target of $215.38, following the company's recent beat on quarterly earnings estimates. Insider selling, including significant sales by EVP Neena M. Patil and SVP Mary E. Henderson, also occurred in the last quarter.
A Voice for Advocacy and Awareness in HER2+ Gastroesophageal Adenocarcinoma - Jazz Pharmaceuticals
Jazz Pharmaceuticals shared a LinkedIn post featuring Nick, a stomach cancer advocate. Nick, who has HER2+ gastroesophageal adenocarcinoma (GEA), emphasizes the importance of a reliable care team and continued research into HER2+ cancers. His story aims to raise awareness and highlight advancements in targeted therapies for this complex disease.
American Nutrition Association Announces Initiative with Jazz Pharmaceuticals to Advance Evidence-Based Sodium Reduction and Cardiovascular Health Education
The American Nutrition Association (ANA) and Jazz Pharmaceuticals have partnered to provide evidence-based nutritional education regarding sodium reduction and cardiovascular health, specifically for individuals with narcolepsy and idiopathic hypersomnia. This initiative aims to equip patients with actionable guidance and healthcare providers with resources to address the elevated cardiovascular and cardiometabolic risks associated with these sleep disorders. The collaboration emphasizes the importance of modifying sodium intake as a critical factor in mitigating cardiovascular risk.
American Nutrition Association Announces Initiative with Jazz Pharmaceuticals to Advance Evidence-Based Sodium Reduction and Cardiovascular Health Education
The American Nutrition Association (ANA) and Jazz Pharmaceuticals have announced a collaboration to educate individuals with narcolepsy and idiopathic hypersomnia on evidence-based sodium reduction strategies. This initiative aims to address the elevated cardiovascular and cardiometabolic risks faced by these patient populations due to high sodium intake. They will develop resources for both patients and clinicians to promote actionable sodium-reduction strategies and improve long-term health outcomes.
How New Ziihera and JZP898 Data from AACR 2026 Will Impact Jazz Pharmaceuticals (JAZZ) Investors
Jazz Pharmaceuticals recently presented new oncology data for Ziihera and JZP898 at AACR 2026. This data offers positive insights into their emerging oncology pipeline, which aims to offset pressures on their older sleep and neuroscience franchises. While promising, investors still need to consider the company's high debt and upcoming patent challenges, with analysts projecting significant revenue and earnings growth for Jazz by 2028.
Jazz Pharmaceuticals’ EBITDA Set to Surge 175% in 2026: Here’s What’s Next
Jazz Pharmaceuticals (JAZZ) achieved a record $4.3 billion revenue in 2025 and is poised for significant growth, with its EBITDA projected to surge 175% in 2026, reaching $2.03 billion. This growth is driven by key product launches and pipeline advancements like zanidatamab and Modeyso, alongside strong performance from existing drugs like Xywav and Epidiolex. Analysts maintain a positive outlook, with a mean price target of $223.50, citing the company's transformative pipeline and strong financial projections despite prior year one-time costs.
How New Ziihera and JZP898 Data from AACR 2026 Will Impact Jazz Pharmaceuticals (JAZZ) Investors
Jazz Pharmaceuticals presented new data on Ziihera and JZP898 at the AACR 2026 meeting, highlighting progress in its oncology pipeline. This data could influence the company's long-term oncology positioning, especially as it aims to offset pressures on its older franchises. Investors should consider how this data impacts the company's financial forecasts and its ability to manage debt and patent challenges.
Jazz Pharmaceuticals plc (JAZZ) reports $1.2 billion Q4 revenue, beats $1.17B estimate
Jazz Pharmaceuticals plc (JAZZ) announced its fourth-quarter revenue of $1.2 billion, which surpassed the analyst estimate of $1.17 billion. This performance indicates stronger-than-expected financial results for the company during the quarter.
Jazz Pharmaceuticals (NASDAQ:JAZZ) Given New $232.00 Price Target at Piper Sandler
Piper Sandler has increased its price target for Jazz Pharmaceuticals (NASDAQ:JAZZ) to $232.00 from $219.00, maintaining an "overweight" rating and suggesting a 28% upside. The company recently beat earnings estimates with an EPS of $6.64 against a consensus of $6.49 and reported $1.20 billion in revenue, an 8.1% year-over-year increase. Despite strong institutional ownership of 89% and a generally positive analyst outlook, insiders have been net sellers, offloading approximately $13.0 million worth of shares.
Goldentree Asset Management LP Takes $149.60 Million Position in Jazz Pharmaceuticals PLC $JAZZ
Goldentree Asset Management LP acquired a significant new stake in Jazz Pharmaceuticals PLC, purchasing over 1.1 million shares valued at approximately $149.6 million. This makes Jazz Pharmaceuticals Goldentree's second-largest holding, representing 1.87% ownership. Other major hedge funds also increased their positions, bringing institutional ownership to 89.14%, while Jazz Pharmaceuticals continues to exceed earnings and revenue expectations.
A Look At Jazz Pharmaceuticals (JAZZ) Valuation As New Oncology Data Heads To The 2026 AACR Meeting
Jazz Pharmaceuticals (JAZZ) is showcasing new oncology data at the 2026 AACR meeting, contributing to a recent positive share price momentum. Despite a 27% one-year return, the stock trades below analyst targets and intrinsic value, suggesting it may still be undervalued. The company's valuation narrative is supported by strong cash flow from neurology and oncology catalysts, with its Q4 2025 revenue beating estimates.
A Look At Jazz Pharmaceuticals (JAZZ) Valuation As New Oncology Data Heads To The 2026 AACR Meeting
Jazz Pharmaceuticals (JAZZ) is presenting new oncology data at the 2026 AACR meeting, featuring zanidatamab, JZP898, and dordaviprone. Despite a recent share price increase and strong Q4 2025 revenue, the stock is considered 21.2% undervalued by Vestra, with a fair value of $228.98 compared to its current $180.45. This valuation relies on continued execution in oncology and sleep, with potential risks from setbacks in zanidatamab approvals or erosion of legacy Xyrem.
Jazz Pharmaceuticals plc (JAZZ) reports $1.2 billion Q4 revenue, beats $1.17B estimate
Jazz Pharmaceuticals plc reported a strong Q4 revenue of $1.2 billion, surpassing analyst estimates of $1.17 billion. This performance highlights the company's financial strength and growth drivers, likely including key product sales and pipeline advancements. The positive earnings report may influence investor confidence and the company's future outlook.
Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026
Jazz Pharmaceuticals will present one oral and six poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The presentations will highlight new insights into zanidatamab's HER2 biology, emerging preclinical data on dordaviprone and related imipridones, and advancing research on JZP898, a conditionally activated IFNɑ2b cytokine. This research demonstrates Jazz's commitment to advancing its oncology portfolio with differentiated science and new insights across multiple development programs.
Faithward Advisors LLC Increases Position in Jazz Pharmaceuticals PLC $JAZZ
Faithward Advisors LLC significantly increased its stake in Jazz Pharmaceuticals PLC by 93.4% in the third quarter, bringing its total holdings to 27,904 shares valued at $3.68 million. This move contributes to the substantial institutional ownership of approximately 89.1% in Jazz Pharmaceuticals, despite recent insider sales. Analysts maintain a "Moderate Buy" rating with an average price target of $214.38, following the company's strong Q3 earnings report.
Ameriprise Financial Inc. Cuts Stock Holdings in Jazz Pharmaceuticals PLC $JAZZ
Ameriprise Financial Inc. reduced its stake in Jazz Pharmaceuticals PLC by 1.1% in the third quarter of the previous year, selling 19,944 shares and retaining 1,847,455 shares valued at $243.49 million. Despite this reduction, other institutional investors have increased their positions in Jazz Pharmaceuticals. The article also provides financial details for Jazz Pharmaceuticals, including recent earnings results, insider trading activity, and analyst ratings, which generally recommend a "Moderate Buy."
Crossmark Global Holdings Inc. Sells 10,433 Shares of Jazz Pharmaceuticals PLC $JAZZ
Crossmark Global Holdings Inc. significantly reduced its stake in Jazz Pharmaceuticals PLC ($JAZZ) by selling 10,433 shares, a 74% reduction, during the third quarter. Despite this, other institutional investors like Vestal Point Capital and AQR Capital Management made substantial additions to their holdings, indicating mixed institutional sentiment. The article also highlights recent insider selling activity and provides an overview of analyst ratings and the company's financial performance.
Capital World Investors Increases Stock Holdings in Jazz Pharmaceuticals PLC $JAZZ
Capital World Investors increased its stake in Jazz Pharmaceuticals PLC by 0.4% in the third quarter of 2025, holding 2,554,867 shares valued at $336.7 million. Despite this, insiders have been net sellers, offloading 68,015 shares worth around $13.04 million in the last 90 days. Analysts remain broadly bullish on JAZZ, with a consensus target price of $214.38, following strong Q3 earnings that beat revenue and EPS estimates.
A Look At Jazz Pharmaceuticals (JAZZ) Valuation After Record Revenue And Supportive Barclays Commentary
Barclays has highlighted Jazz Pharmaceuticals (JAZZ) following its record fourth-quarter revenue, driven by key therapies Xywav, Epidiolex, and Modeyso. Despite a 12.38% jump in share price over the past month, the stock is considered 19% undervalued with a fair value of $228.98 compared to its current $185.43, suggesting potential upside. However, future performance hinges on successful oncology execution and regulatory timelines.
A Look At Jazz Pharmaceuticals (JAZZ) Valuation After Record Revenue And Supportive Barclays Commentary
Barclays has highlighted Jazz Pharmaceuticals (JAZZ) due to strong revenue, particularly from Xywav, Epidiolex, and Modeyso. Despite a recent 12.38% 1-month return and a 38.22% 1-year return, the stock is considered 19% undervalued with a fair value of $228.98, contrasting with its current trading price of around $185.43. While Q4 2025 revenue hit a record $1.20 billion, beating analyst estimates, conservative 2026 revenue guidance slightly tempered investor enthusiasm, placing focus on the company's oncology pipeline and execution.
Jazz Pharmaceuticals (JAZZ) CFO reports tax-withholding share disposition
Jazz Pharmaceuticals' Executive Vice President and Chief Financial Officer, Philip L. Johnson, reported a tax-related disposition of 2,615 ordinary shares on March 5, 2026. These shares, valued at $188.69 each, were withheld to cover tax obligations from the vesting of restricted stock units. Following this transaction, Johnson directly holds 59,608 ordinary shares of Jazz Pharmaceuticals.
Tax-withholding share disposition by Jazz Pharmaceuticals (JAZZ) director
Jazz Pharmaceuticals director Bruce C. Cozadd reported a tax-related disposition where 15,114 Ordinary Shares were withheld at $188.69 per share to cover tax obligations on vested restricted stock units. This transaction, detailed in a Form 4 SEC filing, reduced Cozadd's direct holdings to 390,682 Ordinary Shares and is not considered an open-market trade. The filing notes a neutral sentiment and high impact, clarifying that the shares were withheld for tax purposes rather than being sold.
S&P 500 Futures Fall in Premarket Trading; Jazz Pharmaceuticals, Live Nation Ent Lead
S&P 500 futures experienced a decline in premarket trading. Despite this, Jazz Pharmaceuticals (JAZZ) saw a significant rise of 10.7% and Live Nation Entertainment (LYV) was up 8.9% before market open. The article highlights these key movers ahead of the U.S. stock market opening.
Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Victory Capital Management Inc.
Victory Capital Management Inc. significantly reduced its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 14.5% in the third quarter of 2025. Despite insider selling and a negative net margin, analysts largely maintain a bullish outlook with an average price target of $214.57. Jazz Pharmaceuticals slightly exceeded revenue and EPS expectations in its latest quarter, with institutional investors holding a substantial 89.14% of the stock.
Jazz Pharmaceuticals Revenue Record Puts Focus On Zanidatamab And Valuation
Jazz Pharmaceuticals reported record revenues for 2025 and strong Q4 results, with shares up significantly over the past year. The company filed for regulatory approval of zanidatamab for gastroesophageal adenocarcinoma and is expanding its rare disease portfolio. Investors are focused on upcoming regulatory decisions and clinical data readouts, while Simply Wall St notes the company's debt as a risk.
Jazz Pharmaceuticals Revenue Record Puts Focus On Zanidatamab And Valuation
Jazz Pharmaceuticals reported record revenues for 2025, driven by strong Q4 results and highlighted the completion of regulatory filing for zanidatamab for gastroesophageal adenocarcinoma. The company emphasized the expansion of its rare disease portfolio and upcoming clinical trial readouts. Despite recent stock fluctuations, analysts target a higher price, while Simply Wall St estimates the shares are significantly below fair value.
Neo Ivy Capital Management Takes $1.84 Million Position in Jazz Pharmaceuticals PLC $JAZZ
Neo Ivy Capital Management has established a new position in Jazz Pharmaceuticals PLC, purchasing 13,930 shares valued at approximately $1.84 million. While institutional ownership is high, company insiders have been selling shares, totaling over $13 million in the past 90 days. Despite insider sales, several analysts have issued "Buy" or "Overweight" ratings for Jazz Pharmaceuticals, with an average price target of $214.57.
GW&K Investment Management LLC Sells 17,849 Shares of Jazz Pharmaceuticals PLC $JAZZ
GW&K Investment Management LLC has reduced its stake in Jazz Pharmaceuticals PLC ($JAZZ) by 3.8%, selling 17,849 shares and retaining 454,712 shares valued at approximately $59.93 million. This comes amidst significant insider selling of 73,626 shares totaling around $13.98 million in the past three months, though hedge funds and institutional investors still own 89.14% of the stock. Analysts largely maintain a "Moderate Buy" rating with an average target price of $214.57, following the company's recent earnings beat.
JAZZ SEC Filings - Jazz Pharmaceuticals Plc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Jazz Pharmaceuticals Plc (JAZZ) SEC filings, including 10-K, 10-Q, and 8-K forms, alongside AI-assisted summaries. Recent filings detail insider transactions such as RSU grants and share sales for tax obligations by directors Anne O'Riordan, Norbert G. Riedel, Mark D. Smith, Rick E Winningham, Seamus Mulligan, and CEO Renee D. Gala. Additionally, Form 144 notices indicate proposed sales of vested shares.
